WO/2005/062955 AGONIST ANTI-TRKC ANTIBODIES AND METHODS USING SAME||WO||14.07.2005|
||PCT/US2004/043435||RINAT NEUROSCIENCE CORP.||PONS, Jaume|
The invention concerns agonist anti-trkC antibodies, polypeptides, and polynucleotides encoding the same. The invention further concerns use of such antibodies, polypeptides and/or polynucleotides in the treatment and/or prevention of neuropathies, such as sensory neuropathies, including taxol-induced sensory neuropathy, cisplatin-induced sensory neuropathy, and pyridoxine-induced sensory neuropathy.
WO/2005/063754 TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS||WO||14.07.2005|
||PCT/IB2004/004059||PFIZER LIMITED||BRYANS, Justin, Stephen|
Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: V represents a direct link or -O-; Ring A represents an optionally substituted 5- to 7-membered saturated heterocyclic ring, or a phenylene group.
WO/2005/063739 NOVEL QUINOLINE DERIVATIVES||WO||14.07.2005|
||PCT/IB2004/004151||PFIZER INC.||HONG, Yufeng|
The invention relates to compounds represented by Formula (I): and to pharmaceutically acceptable salts or solvates of said compounds, wherein each of A, R3-8, X3, X5, m, and n are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).
WO/2005/060665 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS||WO||07.07.2005|
||PCT/US2004/042321||INCYTE CORPORATION||XUE, Chu-Biao|
The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula 1: (wherein R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.
WO/2005/060749 SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS||WO||07.07.2005|
||PCT/IB2004/004193||PFIZER LIMITED||BILLEN, Denis|
This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which there is at least one fluorine attached to the cyclopropyl ring, to compositions comprising such compounds, processes to their synthesis and their use as parasticides.
WO/2005/061497 PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS||WO||07.07.2005|
||PCT/IB2004/004013||PFIZER PRODUCTS INC.||BEYER, Thomas, Arthur|
The invention provides compounds of formula (I) prodrugs thereof, and the pharmaceutically acceptable salts of the compounds or prodrugs, wherein n, X, and Y are as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof.
WO/2005/060963 BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY||WO||07.07.2005|
||PCT/IB2004/004056||PFIZER INC.||EDWARDS, Martin, Paul|
The present invention relates to compounds with the formula (I), or a pharmaceutically acceptable salt thereof, wherein: R1 is selected from the group consisting of (C1-C6)alkyl, -(CR3R4)t(C3-C12)cycloalkyl, -(CR3R4)t(C6-C12)aryl, and -(CR3R4)t(4-10)-membered heterocyclyl; b and k are each independently selected from 1 and 2; j is selected from the group consisting of 0, 1, and 2; t, u, p, q, and v are each independently selected from the group consisting of 0, 1, 2, 3, 4, and 5; T is a (6-10)-membered heterocyclyl containing at least one nitrogen atom; R2 is selected from the group consisting of H, (C1-C6)alkyl, -(CR3R4)t(C3-C12)cycloalkyl, -(CR3R4)t(C6-C12)aryl, and -(CR3R4)t(4-10)-membered heterocyclyl; each R3 and R4 is independently selected from H and (C1-C6)alkyl, the carbon atoms of T, R1, R2, R3 and R4 may each be optionally, substituted by I to 5 R5 groups; R5 is defined in the claims; The compounds of the present invention are 11 ß-hsd-1 inhibitors, and are therefore believed to be useful in the treatment of diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, depression, hypertension, and metabolic diseases.
WO/2005/058276 PHARMACEUTICAL ORAL DOSAGE FORM COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY DRUG, AND HAVING GOOG PALATABILITY||WO||30.06.2005|
||PCT/EP2004/014465||AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.||MARCHITTO, Leonardo|
Oral pharmaceutical dosage form comprising tromethamine and a NSAID selected from the group comprising ibuprofen, naproxen and flurbiprofen, characterized in that it also comprises a compound selected from the group comprising glycine, vitamine B6 and mixtures thereof.
WO/2005/054218 NITROOXYDERIVATIVES OF ANTIHYPERTENSIVE DRUGS||WO||16.06.2005|
||PCT/EP2004/013682||NICOX S.A.||DEL SOLDATO, Piero|
The present invention relates to β-adrenergic blockers nitrooxyderivatives of general formula (I): A-(Y-ONO2)s and enantiomers and diastereoisomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them and their use for the treatment of hypertension, cardiovascular diseases, glaucoma, migraine headache and vascular diseases.
WO/2005/052983 THERMIONIC ELECTRIC CONVERTER||WO||09.06.2005|
||PCT/US2003/034501||THERMOCON, INC.||DAVIS, Edwin, D.|
A thermionic electric converter includes a cathode output enhancing laser (374) operable to direct a laser beam (376) to strike an emissive surface of a cathode emitter (321), to increase the electron output of the cathode emitter (321). The cathode output enhancing lase (374) is positioned to direct a laser beam (375) through an opening (370) in the anode (306) or target structure, in the direction of the cathode emitter (321). An electron repulsion ring (380) is provided at an edge of the opening (370) in the anode (306), to reduce the number of electrons missing the anode (306) and passing through the opening (370) in the anode (306).